Core Insights - The strategic cooperation seminar held by Guangzhou Pharmaceutical Group and Guangzhou Baiyunshan Pharmaceutical Group focused on the theme "New Journey Without Boundaries, Together Towards the Future" and gathered over 430 guests from various sectors [1][2] - Guangzhou Pharmaceutical Group aims to achieve modernization, digitalization, technological advancement, and internationalization as part of its "14th Five-Year Plan" to accelerate the goal of "recreating a new Guangzhou Pharmaceutical" [1] Group 1 - Guangzhou Pharmaceutical Group's capital operations are robust, with a fund subscription scale of 4.7 billion yuan and actual contributions of 2.4 billion yuan, focusing on innovative drugs and high-end medical devices [1] - The company is advancing its technological innovation with nearly 20 new drugs under research and 26 new product projects added this year [1] - International expansion is entering a new phase, with ongoing efforts to explore markets in Southeast Asia, the Middle East, and South America [1] Group 2 - A key highlight of the seminar was the announcement of the nuclear medicine industry layout and the innovative achievements of Guangzhou Baiyunshan's nuclear health pharmaceutical company [2] - A strategic cooperation agreement was signed between Baiyunshan and GE Healthcare to empower the high-quality development of the nuclear medicine industry through cross-industry collaboration [2] - The launch of the "China Innovative Drug R&D and Industry Development Research Report Project" aims to integrate resources across the industry chain and address challenges in innovative drug development, supporting China's transition from a major pharmaceutical country to a strong pharmaceutical nation [2]

Investment Rating - The report does not explicitly provide an investment rating for the erectile dysfunction (ED) drug industry in China [1]. Core Insights - The Chinese ED drug market is experiencing strong demand and continuous growth, with a shift from traditional medical needs to broader sexual function enhancement [21]. - The market is characterized by increasing competition from domestic generic drugs and new drug developments, which are expected to intensify in the future [21]. - The leading products in the market, such as Sildenafil (Viagra) and Tadalafil (Cialis), have established strong brand recognition and market presence, making it challenging for new entrants to compete [16]. Summary by Sections Current Competitive Landscape - The competitive landscape of the Chinese ED drug market includes several key players with established products such as Sildenafil, Tadalafil, and others, with varying market entry dates and approval statuses [2]. - As of August 2025, the number of approved drug applications and suppliers for various ED drugs is as follows: Sildenafil (92 approvals, 53 suppliers), Tadalafil (172 approvals, 81 suppliers), and others [2]. Differentiation of New Drugs - New drugs like Sumenafil and Tonafadil are positioned with unique advantages, including lower effective doses, safety profiles, and potential for treating pulmonary arterial hypertension [7][9]. - Sumenafils' clinical trials indicate a lower incidence of adverse reactions compared to existing drugs, enhancing its market appeal [9]. Research Progress of PDE5 Inhibitors - The report highlights the ongoing research and development of PDE5 inhibitors, noting that the market is exploring new structural variants and indications beyond traditional uses [11]. - Traditional Chinese medicine is also recognized for its historical role in treating ED, with various herbal ingredients showing PDE5 inhibitory activity [11]. Market Demand and Future Trends - The demand for ED drugs is driven by both medical needs and psychological factors, with a growing acceptance of sexual health discussions in society [21]. - The market is expected to see an increase in competition from domestic companies entering through generics and innovative formulations, leading to a more dynamic market environment [21].

Group 1 - Kanglongda's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 4.83 million shares [1] - The company specializes in the research, production, and sales of special and ordinary labor protection gloves [1] Group 2 - Haizheng Pharmaceutical's subsidiary plans to collaborate with East China Institute on a biological method for synthesizing heparin, with a project contract amount not exceeding 120 million yuan [2] - The company focuses on the research, production, and sales of chemical raw materials and formulations [3] Group 3 - Tianyin Holdings received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [4] - The company is engaged in the sales of smart terminals, e-commerce, lottery, mobile resale, and mobile internet businesses [4] Group 4 - Shanghai Yashi plans to use up to 200 million yuan of temporarily idle raised funds for cash management in high-security, liquid deposit products [5] - The company specializes in supply chain logistics and execution trade [6] Group 5 - Parker New Materials intends to use 130 million yuan of idle raised funds to purchase structured deposits with expected annual yields between 0.59% and 2.9001% [7] - The company focuses on the research, production, and sales of various types of ring forgings, free forgings, and die forgings [7] Group 6 - Huayang New Materials appointed Jing Hongsheng as the new general manager [8] Group 7 - Liyuan Technology's shareholder plans to reduce holdings by up to 2.03% of the company's shares, totaling no more than 3.04 million shares [9] - The company specializes in the research, design, and integration of environmental water treatment systems and hydrogen fuel cell engine systems [9] Group 8 - Shengnuo Biopharmaceutical's subsidiary received approval for the listing application of Visepegenatide raw materials, a GLP-1 receptor agonist for treating type 2 diabetes and obesity [10][11] - The company focuses on the research, production, and sales of peptide raw materials and formulations [10] Group 9 - Puluo Pharmaceutical plans to repurchase shares worth between 180 million and 360 million yuan, with a maximum price of 23 yuan per share [12] - The company specializes in the research, production, and sales of raw material intermediates and innovative drugs [12] Group 10 - Dongfang Electric's subsidiary plans to establish a joint venture with Anhui Waneng Energy, with a registered capital of approximately 1.857 billion yuan [13] - The company is involved in the development, design, manufacturing, and sales of advanced power generation equipment [13] Group 11 - Hefei China announced that its stock will resume trading on November 20 after completing a review of abnormal trading fluctuations [14] - The company focuses on international trade and after-sales services related to in vitro diagnostic medical devices [14] Group 12 - Dafeng Industrial won a bid for the stage equipment project of the Shenzhen International Performing Arts Center, with a contract amount of 165 million yuan [15] - The company specializes in cultural sports equipment, digital art technology, and operation services [15] Group 13 - Baiyunshan's subsidiary received a drug registration certificate for An Gong Niu Huang Wan in Vietnam [16] - The company is engaged in the research, manufacturing, and sales of traditional Chinese and Western medicines [16] Group 14 - Neusoft Group received a notification to supply intelligent cockpit domain controllers for multiple models from a well-known domestic automobile manufacturer, with an estimated total amount of about 4.2 billion yuan [17] - The company focuses on providing industry solutions and software products [17] Group 15 - Huayu Pharmaceutical's product received overseas marketing approval [18] - The company specializes in the research, production, and sales of innovative and high-quality generic drugs in the oncology field [18] Group 16 - Yao Pi Glass received approval from the CSRC for its stock issuance to specific investors [19] - The company specializes in the production and sales of float glass and processed glass [19] Group 17 - Guangyu Yuan's vice president Wang Junbo resigned due to work adjustments [20] - The company focuses on the production and sales of traditional Chinese medicine products [20] Group 18 - Biyi Co. received approval from the CSRC for its stock issuance to specific investors [21] - The company specializes in the design, manufacturing, and sales of smart small household appliances [21] Group 19 - Sunshine Nuohe's application for acquiring 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through share issuance and convertible bonds has been accepted by the Shanghai Stock Exchange [22] - The company provides comprehensive drug research and development services for domestic pharmaceutical enterprises and research institutions [22] Group 20 - Longxin General plans to increase capital in its wholly-owned subsidiary by no more than 1.65 billion yuan [23] - The company specializes in the research, production, and sales of motorcycles and engines [23] Group 21 - Jiekang Equipment received a corrective order from the Tianjin Securities Regulatory Bureau due to internal control deficiencies [24] - The company specializes in the research, production, and sales of nuclear biochemical safety equipment [24] Group 22 - Wantong Technology plans to raise no more than 920 million yuan through a private placement to supplement working capital [25] - The company focuses on information technology services for highways and ports [25] Group 23 - Dongshan Precision has submitted an application for H-share listing to the Hong Kong Stock Exchange [26] - The company specializes in the research, production, and sales of electronic circuit products and precision components [26] Group 24 - Yonghe Intelligent Control plans to publicly transfer 100% equity of its wholly-owned subsidiary Kunming Medical Oncology Hospital [27] - The company specializes in water and heating valve fittings, tumor precision radiation therapy, and photovoltaic battery businesses [27] Group 25 - Aok Shares signed a strategic cooperation framework agreement with Suzhou Qitian New Materials Co., Ltd. [28] - The company focuses on the research and production of high-end new materials derived from ethylene oxide and ethylene [28] Group 26 - Hongquan Technology's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 299,440 shares [29] - The company specializes in the research, production, and sales of intelligent connected products and software platform development [29] Group 27 - Shilong Industrial's controlling shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 7.2 million shares [30] - The company specializes in the research, production, and sales of chemical products [30] Group 28 - Tangrenshen decided to terminate the investment in the "Dongchong Phase III Pig Breeding Base Construction Project," reallocating the remaining funds of 78.9587 million yuan to supplement working capital [31] - The company specializes in the research, production, and sales of feed, pigs, meat products, and animal health products [31] Group 29 - Gaode Infrared's actual controller plans to reduce holdings by up to 3% of the company's shares, totaling no more than 12.8 million shares [32] - The company specializes in infrared focal plane detector chips and infrared thermal imaging systems [32] Group 30 - Kangyuan Pharmaceutical's actual controller recently increased holdings by 20,000 shares [33] - The company specializes in the research, production, and sales of pharmaceuticals [33] Group 31 - Haida Group plans to repurchase shares worth between 1 billion and 1.6 billion yuan, with a maximum price of 62.00 yuan per share [34] - The company provides overall solutions for animal husbandry [34] Group 32 - Qizhong Technology's 850 million yuan convertible bonds have been approved for listing [35] - The company specializes in advanced packaging and testing of integrated circuits [35] Group 33 - Dingyang Technology launched the new SNA5000B series vector network analyzer [36] - The company specializes in the research, production, and sales of general electronic testing and measuring instruments [36] Group 34 - Airo Energy plans to distribute a cash dividend of 0.9375 yuan per share to all shareholders [37] - The company specializes in photovoltaic energy storage systems and products [37] Group 35 - Hechuan Technology's actual controller and some directors plan to reduce holdings by up to 6% of the company's shares [38] - The company specializes in the research, production, and sales of industrial automation products [38] Group 36 - China First Heavy Industries' chairman was arrested for suspected bribery [39] - The company specializes in heavy machinery manufacturing for various industries [39] Group 37 - Lianhuan Pharmaceutical plans to invest 15 million yuan in joint research with Nanjing University for anti-thrombotic small nucleic acid drugs [40] - The company specializes in the manufacturing and sales of chemical raw materials [40] Group 38 - Anxu Biotech's shareholder plans to reduce holdings by up to 0.94% of the company's shares, totaling no more than 120,000 shares [41] - The company specializes in the research, production, and sales of POCT reagents and instruments [41] Group 39 - Yaxiang Integration's shareholder reduced holdings by 130,000 shares [42] - The company specializes in providing cleanroom engineering and related services for high-tech electronic industries [42] Group 40 - Zhongwen Media plans to use up to 9.5 billion yuan of idle funds to purchase financial products [43] - The company specializes in traditional publishing and various new media businesses [43]

Core Viewpoint - The company has received a registration certificate for its product An Gong Niu Huang Wan from the Traditional Medicine Department of the Vietnamese Ministry of Health, which will enhance its market presence in Vietnam [1] Group 1: Company Developments - The registration certificate was issued to the company's wholly-owned subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. [1] - The product will be sold in Vietnam through an authorized distributor, TNHH NEWSEEN COAST [1] - This development is expected to improve the company's product competitiveness in the Vietnamese market [1] Group 2: Financial Impact - The receipt of the registration certificate for An Gong Niu Huang Wan is not expected to have a significant impact on the company's current financial performance [1]

Core Viewpoint - The company has received a registration certificate for Angong Niuhuang Pills from the Traditional Medicine Administration of the Vietnamese Ministry of Health, which will enhance its market presence in Vietnam [1] Group 1: Company Developments - Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, submitted the registration application for Angong Niuhuang Pills on June 20, 2024 [1] - The Angong Niuhuang Pills are indicated for clearing heat and detoxifying, as well as calming and opening the orifices [1] - Following the receipt of the registration certificate, the product will be sold in Vietnam through an authorized distributor, TNHH NEWSEEN COAST [1] Group 2: Market Expansion - The registration of Angong Niuhuang Pills is expected to help the company expand its business in the Vietnamese market [1] - This move is anticipated to enhance the competitiveness of the company's products in the region [1]

Core Viewpoint - The company has received a registration certificate for its product An Gong Niu Huang Wan from the Traditional Medicine Management Bureau of the Vietnamese Ministry of Health, which will enhance its market presence in Vietnam [1] Group 1: Company Developments - The registration certificate for An Gong Niu Huang Wan was issued to the company's wholly-owned subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd [1] - The product will be sold in Vietnam through an authorized distributor, TNHH NEWSEEN COAST, facilitating the company's expansion into the Vietnamese market [1] - The registration is not expected to have a significant impact on the company's current financial performance [1]

Group 1 - The core point of the article is that Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., a wholly-owned subsidiary of Baiyunshan, has received a registration certificate for the traditional Chinese medicine An Gong Niu Huang Wan from the Traditional Medicine Management Department of the Vietnamese Ministry of Health [1] - An Gong Niu Huang Wan is classified as a prescription traditional Chinese medicine, with its main functions being to clear heat and detoxify, as well as to calm and open the orifices [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司收到越南藥品註冊證書的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年11月19日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025－079 广州白云山医药集团股份有限公司 关于子公司收到越南药品注册证书的公告 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 注册持有人：TNHH NEWSEEN COAST 制造商：广州白云山中一药业有限公司 二、药品的其他相关情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记 ...

剂型：丸剂 类别：处方中成药 注册编号：VNCT-00006-25 注册持有人：TNHH NEWSEEN COAST 制造商：广州白云山中一药业有限公司 证券代码：600332 证券简称：白云山 公告编号：2025－079 广州白云山医药集团股份有限公司 关于子公司收到越南药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 全资子公司广州白云山中一药业有限公司（以下简称"中一药业"）收 到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书。现将相关情 况公告如下： 一、药品的基本情况 名称：安宫牛黄丸（Angong Niuhuang Pills） 根据米内网数据显示，2024年安宫牛黄丸在中国城市、县级公立医 院和城市、网上药店的销售额为人民币498,242万元。2024年中一药业安 1 宫牛黄丸的销售收入为人民币15,611.83万元。 截至本公告日，中一药业在安宫牛黄丸药品研发项目上已累计投入 研发费用合计约人民币3,279.81万元（未审计）。 三 ...

Core Viewpoint - The company has received a registration certificate for its product An Gong Niu Huang Wan from the Traditional Medicine Management Department of the Vietnamese Ministry of Health, which will enhance its market presence in Vietnam [1] Group 1: Product Registration - The registration certificate for An Gong Niu Huang Wan allows the product to be sold in Vietnam through TNHH NEWSEEN COAST, a company authorized by 中一药业 [1] - An Gong Niu Huang Wan is indicated for clearing heat and detoxifying, as well as calming and opening the orifices [1] Group 2: Market Expansion - The registration is expected to help 中一药业 expand its business operations in the Vietnamese market, thereby improving the competitiveness of its products [1] - The impact of this registration on the company's current performance is not significant [1]